Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors: an analysis of the UK Biobank
=======================================================================================================================================

* Maxine Sun
* Marie-Christyne Cyr
* Johanna Sandoval
* Louis-Philippe Lemieux Perreault
* Lambert Busque
* Jean-Claude Tardif
* Marie-Pierre Dubé

## ABSTRACT

Cancer survivors are at an increased risk of cardiovascular disease (CVD) compared to the general population. Here, we evaluated the impact of somatic mosaic chromosomal alterations (mCAs) on death of CVD causes, coronary artery disease (CAD) causes, from cancer, and of any cause in patients with a cancer diagnosis within the UK Biobank (n=48 919). mCAs were derived from DNA genotyping array intensity data and long-range chromosomal phase inference from participants. Overall, 10 070 individuals (20.6%) carried ≥1 mCA clone. In adjusted analyses, mCA was associated with an increased risk of death of CAD causes (hazard ratio [HR]: 1.37, 95% confidence interval [CI]: 1.09-1.71, *P*=0.006), from cancer (HR: 1.06, 95% CI: 1.00-1.11, *P*=0.041), and death of any cause (HR: 1.07, 95% CI: 1.02-1.12, *P*=0.005). Among cancer survivors, carriers of any mCA are at an increased risk of death of CAD causes and of any cause as compared to non-carriers.

Keywords
*   clonal hematopoiesis
*   CHIP
*   mosaic chromosomal alterations
*   cardiovascular mortality
*   UK Biobank

## INTRODUCTION

The number of survivors of cancer is growing worldwide due to the ageing populations and improvements in early cancer detection and treatment modalities.1 It is estimated that over 26 million people in the United States alone will be living with a history of cancer by the year 2040.2,3 Among cancer survivors, a pressing clinical problem is their increased predisposition to cardiovascular disease (CVD)4,5 and treatment-related cardiac dysfunction6,7. Currently, there are no guideline recommendations with respect to CVD screening for patients with cancer, possibly stemming from the lack of CVD-related markers that can better risk-stratify cancer patients beyond existing cardiovascular risk factors for the general population.8 The identification and development of biomarkers that can eventually be used towards a risk assessment tool for the purpose of discriminating patients diagnosed with cancer who are at a higher risk of CVD may be useful.8

Clonal Hematopoiesis (CH) refers to a population of cells derived from a mutated multipotent stem/progenitor cell occurring in the context of aging.9 CH can be caused by somatic mutation in driver genes10-14 called clonal hematopoiesis of indeterminate potential (CHIP)15, or by somatic mosaic chromosomal alterations (mCA).16-20 Previously, CHIP has been associated with a greater burden of atherosclerotic vessel disease21, a higher risk of myocardial infarction22,23, inflammatory response24, and death of any cause11,12. The presence of CHIP has also been associated with treatment-related adverse outcomes in cancer survivors.25,26

Somatic mCAs correspond to large chromosomal gains, loss, or copy neutral losses of heterozygosity which can affect autosomes or sexual chromosomes.27 The most prevalent mCA is the loss of the Y chromosome in aging men.28 Mosaic loss of the Y chromosome has been associated with all-cause mortality29,30, Alzheimer’s disease31, autoimmune disease32, diabetes29, and cardiovascular events33.

Given the links between CH and CVD in the normal aging population, and the paucity of data in cancer survivors, we sought to evaluate the impact of mCAs on the risk of death from CVD causes, from cancer, and of any cause among cancer survivors at risk of CVD by relying on DNA genotyping array intensity data and long-range chromosomal phase information inferred from participants of the UK Biobank. Our hypothesis was that carriers of any mCA would be at higher risk of death from CVD causes compared to their mCA non-carriers.

## Results

### Baseline characteristics and mCA prevalence

Overall, 48 919 participants were diagnosed with bladder, larynx, corpus uteri, prostate, rectal, breast, kidney, non-Hodgkin lymphoma, melanoma, or lung cancer within the UK Biobank (**Table 1**). The mean age at study entry was 60 years old (median 62, interquartile range [IQR]: 56-65). Forty-six percent (45.8%) were men and 39.6% previously smoked.

View this table:
[Table 1.](http://medrxiv.org/content/early/2022/08/22/2022.08.20.22279019/T1)

Table 1. 
Summary descriptives of patients with a cancer diagnosis according to mosaic chromosomal alterations status. mCA: mosaic chromosomal alteration; IQR: interquartile range; SD: standard deviation; CVD: cardiovascular disease; CAD: coronary artery disease

The presence of at least one mCA clone was observed in 20.6% (10 070/48 919) of patients **(Suppl. Materials, sFigure 1A)**. Of those, 2 432 were autosomal carriers and 1 910 had mCA in ≥10% of peripheral leukocytes, defined as an expanded mCA clone. Whereas most carriers had only one mCA, 812 individuals carried ≥2 non-overlapping mCAs. In general, those with mCA were older (median 64 vs. 61 years), where the prevalence of mCA increased with increasing age categories: 4.8% among those aged <49 years old, 12.1% for those aged 50-59 years old, 26.4% for those aged 60-69 years old, and 30.4% for those aged ≥70 years old (**Suppl. Materials, sFigure 1B**). Expectedly, 73.6% of patients with mCA were men, likely because the majority of mCA carriers was due to loss of the Y chromosome (n=6 558). In comparison, mCA due to loss of the X chromosome was observed in 1 641 patients (16.3%). Amongst patients older than 65 years old, the prevalence of mCA according to cancer types was the lowest for breast cancer (14%) and the highest for larynx cancer (43%, **Suppl. Materials, sFigure 1C**).

### mCA and the risk of death of CVD causes, coronary artery disease (CAD) causes, from cancer, and any cause

In adjusted Cox regression analyses, mCA was associated with an increased risk of death of coronary artery disease (CAD) causes (hazard ratio [HR]: 1.37, 95% confidence interval [CI]: 1.09-1.71, *P*=0.006), death from cancer (HR: 1.06, 95% CI: 1.00-1.11, *P*=0.041), and death of any cause (HR: 1.07, 95% CI: 1.02-1.12, *P*=0.005, **Figure 1**). These effects were maintained after the additional adjustment for hypertension and body-mass index in sensitivity analyses (**Suppl. Materials, sTable 1**). Sub-analyses according to smoking status showed that mCAs were associated with significantly higher risks of death of CVD causes (smoking-by-mCA *P*interaction=0.044), and death of any cause (smoking-by-mCA *P*interaction=0.011), but not with death of CAD-causes (smoking-by-mCA *P*interaction=0.50) or with death from cancer (smoking-by-mCA *P**interaction*=0.266, **Suppl. Materials, sTable 2**). In sub-analyses considering chemotherapy, chemotherapy-by-mCA interaction terms were not significant for any of the primary endpoints (all *P*interaction≥0.05, **Suppl. Materials, sTable 3**).

![Figure 1.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/08/22/2022.08.20.22279019/F1.medium.gif)

[Figure 1.](http://medrxiv.org/content/early/2022/08/22/2022.08.20.22279019/F1)

Figure 1. 
Multivariable Cox regression models evaluating the effect of mosaic chromosomal alterations on death of cardiovascular disease causes, of coronary artery disease causes, from cancer, and death of any cause. All models are adjusted for age at baseline, sex, smoking status, chemotherapy, radiotherapy, number of days between the date of recruitment and the date of cancer diagnosis, and principal components 1 to 10. CAD: coronary artery disease, CI: confidence interval, CVD: cardiovascular disease, HR: hazard ratio, mCA: mosaic chromosomal alterations, Ref.: referent category (1.0)

Different types of mCAs had different effects on the study endpoints. Notably, autosomal mCAs were associated with death of CVD causes (HR: 1.35, 95% CI: 1.04-1.75, *P*=0.023), with death from cancer (HR: 1.14, 95% CI: 1.04-1.24, *P*=0.004), as well as with death of any cause (HR: 1.14, 95% CI: 1.06, 1.24, *P*<0.001, **Suppl. Materials, sTable 4**). mCA due to loss of the X chromosome was associated with death of CAD causes (HR: 2.02, 95% CI: 1.16, 3.54, *P*=0.013, **Suppl. Materials, sTable 5**), and mCA due to loss of the Y chromosome was associated with death of any cause (HR: 1.08, 95% CI: 1.02-1.14, *P*=0.009, **Suppl. Materials, sTable 6**). Expanded mCAs taken individually had no statistically significant impact on the primary endpoints (**Suppl. Materials, sTable 7**). When considering the study population of 479 435 participants with, and without a history of any cancer, the interaction terms between cancer and mCA were significant for death from cancer (*P*interaction<0.001) and death of any cause (*P*interaction<0.001, **Suppl. Materials, sTable 8**). On the other hand, the interaction terms between cancer status and mCA for death of CVD causes and CAD causes were not statistically significant (**Suppl. Materials, sTable 8**).

### mCA and the risk of death of CVD causes, CAD causes, from cancer, and any cause according to cancer site

In multivariable analyses where the effect of mCA was assessed in subgroups according to cancer type, we found that carriers of mCAs diagnosed with kidney cancer had an increased risk of death of CVD causes (HR: 2.03, 95% CI: 1.11-3.72, *P*=0.022) and CAD causes (HR: 3.57, 95% CI: 1.44-8.84, *P*=0.006, **Suppl. Materials, sTables 9 & 10**) compared to their mCA non-carriers counterparts diagnosed with kidney cancer. Women diagnosed with breast cancer who carried a mCA also had a higher risk of death of CAD causes (HR: 2.46, 95% CI: 1.23-4.92, *P*=0.011). mCA had no significant impact on deaths from cancer in either cancer type (**Suppl. Materials, sTable 11**). Women carriers of mCA diagnosed with corpus uteri cancer had an increased risk of death of any cause (HR: 1.35, 95% CI: 1.01-1.80, *P*=0.042, **Suppl. Materials, sTable 12**).

### mCA and the risk of incident CV endpoints (exploratory analyses)

In the overall cohort of cancer survivors (n=48 919), carriers of mCA had a higher risk of incident ST-elevation myocardial infarction (STEMI) (HR: 1.19, 95% CI: 1.03-1.37, *P*=0.022) and peripheral vascular disease (HR: 1.17, 95% CI: 1.04-1.31, *P*=0.007, **Figure 2**) than mCA non-carriers. Amongst those aged 65 years and above, carriers of mCA showed a higher risk of incident STEMI (HR: 1.23, 95% CI: 1.02-1.49, *P*=0.034), non-STEMI (HR: 1.20, 95% CI: 1.03-1.40, *P*=0.020), stable angina (HR: 1.20, 95% CI: 1.00-1.44, *P*=0.047), intracerebral hemorrhage (HR: 1.22, 95% CI: 1.01-1.48, *P*=0.038), subarachnoid hemorrhage (HR: 1.23, 95% CI: 1.01-1.50, *P*=0.040), and peripheral vascular disease (HR: 1.20, 95% CI: 1.03-1.39, *P*=0.017, **Suppl. Materials, sTable 13**).

![Figure 2.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/08/22/2022.08.20.22279019/F2.medium.gif)

[Figure 2.](http://medrxiv.org/content/early/2022/08/22/2022.08.20.22279019/F2)

Figure 2. 
Multivariable Cox regression models evaluating the effect of mosaic chromosomal alterations on incident cardiovascular phenotypes. All models are adjusted for age at baseline, sex, smoking status, chemotherapy, radiotherapy, number of days between the date of recruitment and the date of cancer diagnosis, and principal components 1 to 10. CVD: cardiovascular disease, CI: confidence interval, HR: hazard ratio, mCA: mosaic chromosomal alteration, MI: myocardial infarction, NSTEMI: non-ST-elevation myocardial infarction, STEMI: ST-elevation myocardial infarction, TIA: transient ischemic attack.

## DISCUSSION

Here, we assessed the impact of somatic mCAs, a subtype of CH, on the risks of death of CVD causes, CAD causes, from cancer, and death of any cause focusing exclusively on individuals diagnosed with one of 10 cancer types known to have the highest reported rates of CVD deaths34. First, we found that carriers of mCAs had an increased risk of death of CAD causes, from cancer, and of any cause. Some of the associations were more impactful in mCA subtypes, notably autosomal mCAs were associated with the risk of death of CVD causes, mCA due to loss of the X chromosome was associated with the risk of death of CAD causes, and mCA due loss of the Y chromosome was associated with the risk of death of any causes.

Second, exploratory analyses suggest that carriers of mCAs were at higher risk of incident STEMI and peripheral vascular disease; and for cancer survivors aged >65 years, at a higher risk of incident NSTEMI, stable angina, intracerebral hemorrhage, and subarachnoid hemorrhage. In comparison, a previous mCA study focusing on MI and stroke did not find any significant associations when focusing on carriers of expanded mCAs, regardless of cancer status.20 The current study suggests that any mCA carrier status can be prognostic of several other CV phenotypes in cancer survivors. Previous research looking at mutation driven CH have correlated mutations in *DNMT3A* and *TET2* with chronic heart failure in patients with STEMI (n=485).35 In another study including approximately 50 000 samples with exome sequencing data, Zekavat et al.26 found that carriers of CHIP mutations had higher risks of peripheral artery disease. Third, when considering cancer survivors, it is possible that cancer-directed treatments may have perpetuated the influence of mCA on outcomes.25 However, our sub-analyses which included a chemotherapy-by-mCA interaction term failed to reach statistical significance, albeit a near 2-fold increased risk of death of CAD causes for mCA carriers. Previous work have supported the hypothesis that chemotherapy may lead to clonal expansion of mutations in apotosis or DNA repair gens (*TP53, PPM1D*)25,36, and that CHIP mutations caused by these genes could worsen the risk of atherosclerosis26. It is possible that chemotherapy usage may not be well-captured in the current database. Furthermore, without knowledge on tumor aggressiveness in the current database, it was not possible to exclude the presence of a selection bias where carriers of mCAs may be at a more advanced stage of the disease or have a more aggressive tumor histology, which may make them more likely to undergo additional lines of chemotherapy, which could have contributed to their risks of CVD. It will be critical to evaluate whether cancer-directed treatments have an additive or synergistic influence on mCAs. Further research will be needed to understand the impact of mCAs on CVD outcomes following modern standards of care, such as treatment with immune-checkpoint inhibitors. In that scenario, mCA carriers may benefit from an in-depth preventive cardiology approach prior to treatment where multi-disciplinary cardio-oncology care could mitigate such risks.

Fourth, we found that the effect of mCA on the risks of death of CVD and CAD causes, as well as of death of any cause was specific to previous smokers. This upholds the findings of a recent study which established strong causal associations between smoking and mCAs, and postulated that smoking may contribute to the selection of clones bearing somatic mutations.37 Indeed, we found that cancer survivors who are carriers of mCAs may face added risks if they were previous smokers. Additional work is required to better evaluate how smoking habits can impact mCAs and the downstream consequences of such mutations, especially in patients diagnosed with cancer.

Nevertheless, the generalizability of our findings may be limited as the influence of mCA was not consistent across all examined cancer types. This was not entirely unexpected given the heterogeneous biology of cancers included and distinct mechanisms of mCAs with respect to these cancers and treatments that patients received. Even so, the associations observed within this study may inform future studies focusing on the effect of mCA and the risks of death from CVD causes for specific cancer types.

Our study has additional limitations. First, our study did not consider CHIP mutations. While the association of CHIP mutations with CVD has been established, it has not been formally tested in patients diagnosed exclusively with non-hematologic cancer. There is reason to believe that carriers of CHIP mutations in addition to being diagnosed with cancer may face higher risks of CVD. In addition, the synergistic effect of both mCA and CHIP mutation carriers amongst cancer survivors will be of interest to explore in future studies. Second, It has been established that detectable hematopoietic loss of the X and Y chromosomes increase with age, with more age-related pathologies in older individuals than in younger individuals.38,39 Unexpectedly, the association between the mosaic loss of the Y chromosome and death of CVD causes was not significant in the current analysis that focused on cancer survivors. The non-significant association may have been related to mosaic loss of the Y chromosome definition used, where a larger percentage threshold of blood cells lacking chromosome Y may be more relevant. For example, a recent analysis found that regardless of their cancer status, men with mosaic loss of the Y chromosome in 40% or more of leukocytes displayed a 31% increased risk of dying from any disease related to the circulatory system based on survival data from the UK Biobank.39 In contrast, the relative risk per 1% increase of detectable loss of Y chromosome and the risk of death from CVD causes was more subdued (HR: 1.0054, *P*=0.001).39 We did also note that mosaic loss of the Y chromosome was rather impactful for cancer-specific mortality, which may be relevant in considering the significant association found between loss of the Y chromosome and death of any cause. Third, mCA status was evaluated only at study entry. Reasonably, clones carrying a mCA may undergo rapid changes following various environmental exposures (e.g. smoking, chemotherapy). Under this premise, serial measurements of mCA may better help inform the dose-response effect of such factors and mCA. Finally, while adjustment was made for chemotherapy and radiotherapy treatment, some individuals may have undergone such treatments in the outpatient setting, which would not have been properly captured using inpatient procedural codes.

In conclusion, our study showed that mCAs are associated with higher risks of death of CAD causes among cancer survivors. mCAs were also associated with higher risks of death from cancer and death of any cause. Notably, autosomal mCAs appeared to be driving most of the observed associations. Future studies may focus on specific cancer types and their treatments to better ascertain the effect of mCA on the risk of CVD and evaluate if they constitute a useful biomarker in the management of cancer survivors.

## METHODS

### Study samples

The UK Biobank is a large population-based cohort that includes over 500,000 participants aged between 40-70 years old, recruited from 2006 to 2010.40 Baseline interviews regarding their medical history and environmental exposures were conducted in the UK across 22 assessment centers where blood samples for genotyping were also obtained and blood analysis performed. Additional health outcome data, including diagnoses of cancer and CVD, have been linked via UK national registries and hospital records managed by the NHS, and genome-wide genotyping of blood-derived DNA was performed by the UK Biobank using 2 genotyping arrays sharing 95% of marker content: Applied Biosystems UK BiLEVE Axiom Array and Applied Biosystems UK Biobank Axiom Array, both by Affymetrix.41

### Determination of mosaic chromosomal alterations

Previously, Loh et al.20 identified mosaic chromosomal alteration in 487 409 genotyped individuals. As previously described19,20, mCAs were determined from genotype intensities log2R ratio (LRR) and B-allele frequency (BAF) values, which were used to estimate the total and relative allelic intensities, respectively. Re-phasing was conducted using Eagle242 and mCA calling was performed by leveraging long-range phase information searching for allelic imbalances between maternal and paternal allelic fractions across contiguous genomic segments. For the purpose of our study, mCA calls were obtained from dataset Return 3094 from the UK Biobank application 19808.20,42 From the genetic data of the UK Biobank, 479 435 individuals who passed the sample quality control criteria, including genotypic-phenotypic sex concordance, and without first or second-degree relatives in the dataset were considered (**Figure 3**). Of those, we identified 48 919 participants with a diagnosis of cancer before or after the baseline assessment visit based on the cancer register, using ICD-9 and ICD-10 diagnostic codes for bladder, larynx, prostate, corpus uteri, rectum, breast, kidney, non-Hodgkin lymphoma, melanoma of the skin, or lung cancer (**Suppl. Materials, sTable 14)**. These specific cancer types were selected based on a previous publication which identified the top 10 cancer sites with the largest percentage of deaths attributed to CVD.34

![Figure 3.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/08/22/2022.08.20.22279019/F3.medium.gif)

[Figure 3.](http://medrxiv.org/content/early/2022/08/22/2022.08.20.22279019/F3)

Figure 3. 
Visual representation of the study flow.

### Exposure and clinical outcomes

The exposure of interest was the presence of a mCA of any type, which was classified as ≥1 or none. mCAs were also categorized as autosomal mCAs, loss of the X chromosome, loss of the Y chromosome, and expanded mCAs (defined as mCAs present in at least 10% of peripheral leukocyte DNA indicative of clonal expansion43). The study primary endpoints consisted of death of CVD causes, death of CAD causes, death from cancer, and death of any cause based on ICD-10 codes for primary cause of death from the death register records (**Suppl. Materials, sTable 15**). For each endpoint, the time to death was calculated from the date of the assessment visit at the time of recruitment into the UK Biobank (baseline) if patients’ cancer diagnosis occurred *before* baseline, and alternatively, from the date of cancer diagnosis if the cancer diagnosis occurred *after* baseline. The number of days between a patient’s cancer diagnosis date and baseline was recorded, and it was set as 0 if the cancer diagnosis occurred after baseline. For individuals who were not deceased, the end of follow-up was the last date of death registered based on participant’s country of enrolment (i.e., 2021-03-30 for England, 2021-03-23 for Scotland and 2021-03-16 for Wales).

Other exploratory endpoints included various incident CV phenotypes44 recorded after patients’ cancer diagnosis date (**Suppl. Materials, sTable 15**). For these endpoints, the time to the event (i.e., incident CV event of interest or death of CVD causes) was calculated from the date of cancer diagnosis. For those who did not experience any incident CV events, censor date was set to the date of death of non-CVD causes, or the last hospitalization date known for each patient.

### Statistical analyses

In our primary analyses focusing on the association between mCAs and death of CVD causes, CAD causes, from cancer, and death of any cause, Cox proportional hazards regression models were used, adjusting for age at baseline, sex, smoking status, treatment with chemotherapy and/or radiotherapy, the number of days between cancer diagnosis and date of baseline, and principal components for genetic ancestry (PC, 1-10). An mCA-by-cancer status interaction term was also assessed with respect to each of the primary endpoints in the overall population including individuals without any history of cancer (n=479 435). We further examined the associations of mCA types (autosomal mCAs, mosaic loss of the Y chromosome, mosaic loss of the X chromosome, and expanded mCAs) on the primary endpoints of interest. Sensitivity analyses considered the additional adjustment for hypertension and body mass index. Cox regression models were also used for exploratory analyses of incident CV phenotypes. Sub-group analyses were conducted according to cancer types, smoking status, treatment with chemotherapy, and age at baseline dichotomized at 65 years. All analyses were performed using the survival package in R (version 4.1.2, Bird Hippie). All analytical and summary reports were produced with gtsummary (version 1.6.1).45

## Supporting information

sFigure 1 [[supplements/279019_file06.pdf]](pending:yes)

Supplementary Materials [[supplements/279019_file07.xlsx]](pending:yes)

## Data Availability

All data produced in the present study are available upon reasonable request to the authors

## Figure Legends

**sFigure 1**. Visual depiction of the proportion of patients with at least 1 mosaic chromosomal alteration in the overall cohort (A), of the proportion of patients with at least one mosaic chromosomal alteration stratified according to age groups (B), and of the proportion of patients with at least one mosaic chromosomal alteration stratified according to cancer types (C). mCA: mosaic chromosomal alteration.

## Acknowledgements

We thank the UK Biobank for providing the data under Application Number 20168.

## Footnotes

*   **Disclosures/Conflicts of interest:** M-P.D. has received personal fees and reports minor equity interest in Dalcor Pharmaceuticals. M-P.D. has a patent Methods for Treating or Preventing Cardiovascular Disorders and Lowering Risk of Cardiovascular Events issued to Dalcor Pharmaceuticals, no royalties received; a patent Genetic Markers for Predicting Responsiveness to Therapy with HDL-Raising or HDL Mimicking Agent issued to Dalcor Pharmaceuticals, no royalties received; and a patent Methods for using low dose colchicine after myocardial infarction, assigned to the Montreal Heart Institute.
    
    J-C.T. reports research grants from Amarin, AstraZeneca, Ceapro, DalCor Pharmaceuticals, Esperion, Ionis, Novartis, Pfizer, and RegenXBio; honoraria from AstraZeneca, DalCor Pharmaceuticals, HLS Pharmaceuticals, Pendopharm and Pfizer; minor equity interest from Dalcor Pharmaceuticals; and authorship on a patent Methods for Treating or Preventing Cardiovascular Disorders and Lowering Risk of Cardiovascular Events issued to Dalcor Pharmaceuticals, no royalties received; a patent Genetic Markers for Predicting Responsiveness to Therapy with HDL-Raising or HDL Mimicking Agent issued to Dalcor Pharmaceuticals, no royalties received; a pending patent Early administration of low-dose colchicine after myocardial infarction, and a patent Methods for using low-dose colchicine after myocardial infarction, assigned to the Montreal Heart Institute (J-C.T. has waived his rights in the colchicine patents).
    
    Other authors have nothing to declare.

*   **Funding** M.S. was funded by a doctorate scholarship from the Fonds de Recherche du Québec - Santé (FRQS). M-P.D. and J-C.T. hold Canada Research Chairs. This project was funded in part by the Health Collaboration Acceleration Fund (FACS) from the Government of Quebec (J-C.T. principal investigator and M-P.D. co-principal investigator).

*   Received August 20, 2022.
*   Revision received August 20, 2022.
*   Accepted August 22, 2022.


*   © 2022, Posted by Cold Spring Harbor Laboratory

This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)

## References

1.  Coleman, M. P. et al. EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Annals of oncology : official journal of the European Society for Medical Oncology 14 Suppl 5, v128–149, doi:10.1093/annonc/mdg756 (2003).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/annonc/mdg756&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=14684503&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2022.08.20.22279019.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000207720700007&link_type=ISI) 

2.  Bluethmann, S. M., Mariotto, A. B. & Rowland, J. H. Anticipating the “Silver Tsunami”: Prevalence Trajectories and Comorbidity Burden among Older Cancer Survivors in the United States. Cancer Epidemiology, Biomarkers & Prevention 25, 1029–1036, doi:10.1158/1055-9965.EPI-16-0133 (2016).
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoiY2VicCI7czo1OiJyZXNpZCI7czo5OiIyNS83LzEwMjkiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMi8wOC8yMi8yMDIyLjA4LjIwLjIyMjc5MDE5LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

3.  Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2016. CA: A Cancer Journal for Clinicians 66, 7–30, doi:[https://doi.org/10.3322/caac.21332](https://doi.org/10.3322/caac.21332) (2016).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3322/caac.21332&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=26742998&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2022.08.20.22279019.atom) 

4.  Armenian, S. H. et al. Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 34, 1122–1130, doi:10.1200/jco.2015.64.0409 (2016).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1200/jco.2015.64.0409&link_type=DOI) 

5.  Haugnes, H. S. et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 28, 4649–4657, doi:10.1200/jco.2010.29.9362 (2010).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1200/jco.2010.29.9362&link_type=DOI) 

6.  Emery, J. et al. Management of common clinical problems experienced by survivors of cancer. Lancet (London, England) 399, 1537–1550, doi:10.1016/s0140-6736(22)00242-2 (2022).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/s0140-6736(22)00242-2&link_type=DOI) 

7.  Moslehi, J. J., Salem, J.-E., Sosman, J. A., Lebrun-Vignes, B. & Johnson, D. B. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. The Lancet 391, 933, doi:10.1016/S0140-6736(18)30533-6 (2018).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0140-6736(18)30533-6&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2022.08.20.22279019.atom) 

8.  Lamberg, M. et al. Next Generation Risk Markers in Preventive Cardio-oncology. Current Atherosclerosis Reports, doi:10.1007/s11883-022-01021-x (2022).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s11883-022-01021-x&link_type=DOI) 

9.  Khoury, J. D. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 36, 1703–1719, doi:10.1038/s41375-022-01613-1 (2022).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41375-022-01613-1&link_type=DOI) 

10. Busque, L. et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet 44, 1179–1181, doi:10.1038/ng.2413 (2012).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/ng.2413&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=23001125&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2022.08.20.22279019.atom) 

11. Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. The New England journal of medicine 371, 2488–2498, doi:10.1056/NEJMoa1408617 (2014).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa1408617&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25426837&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2022.08.20.22279019.atom) 

12. Genovese, G. et al. Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence. New England Journal of Medicine 371, 2477–2487, doi:10.1056/NEJMoa1409405 (2014).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa1409405&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25426838&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2022.08.20.22279019.atom) 

13. Xie, M. et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 20, 1472–1478, doi:10.1038/nm.3733 (2014).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/nm.3733&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25326804&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2022.08.20.22279019.atom) 

14. Mckerrell, T. et al. Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. Cell Rep 10, 1239–1245, doi:10.1016/j.celrep.2015.02.005 (2015).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.celrep.2015.02.005&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25732814&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2022.08.20.22279019.atom) 

15. Steensma, D. P. et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 126, 9–16, doi:10.1182/blood-2015-03-631747 (2015).
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTI6ImJsb29kam91cm5hbCI7czo1OiJyZXNpZCI7czo3OiIxMjYvMS85IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjIvMDgvMjIvMjAyMi4wOC4yMC4yMjI3OTAxOS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

16. Laurie, C. C. et al. Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet 44, 642–650, doi:10.1038/ng.2271 (2012).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/ng.2271&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=22561516&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2022.08.20.22279019.atom) 

17. Jacobs, K. B. et al. Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet 44, 651–658, doi:10.1038/ng.2270 (2012).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/ng.2270&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=22561519&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2022.08.20.22279019.atom) 

18. Forsberg, L. A. et al. Age-related somatic structural changes in the nuclear genome of human blood cells. American journal of human genetics 90, 217–228, doi:10.1016/j.ajhg.2011.12.009 (2012).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.ajhg.2011.12.009&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=22305530&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2022.08.20.22279019.atom) 

19. Loh, P.-R. et al. Insights into clonal haematopoiesis from 8,342 mosaic chromosomal alterations. Nature 559, 350–355, doi:10.1038/s41586-018-0321-x (2018).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41586-018-0321-x&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=29995854&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2022.08.20.22279019.atom) 

20. Loh, P.-R., Genovese, G. & Mccarroll, S. A. Monogenic and polygenic inheritance become instruments for clonal selection. Nature 584, 136–141, doi:10.1038/s41586-020-2430-6 (2020).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41586-020-2430-6&link_type=DOI) 

21. Jaiswal, S. et al. Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. The New England journal of medicine 377, 111–121, doi:10.1056/NEJMoa1701719 (2017).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa1701719&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=28636844&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2022.08.20.22279019.atom) 

22. Bick, A. G. et al. Genetic Interleukin 6 Signaling Deficiency Attenuates Cardiovascular Risk in Clonal Hematopoiesis. Circulation 141, 124–131, doi:10.1161/circulationaha.119.044362 (2020).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1161/CIRCULATIONAHA.119.044362&link_type=DOI) 

23. Honigberg, M. C. et al. Premature Menopause, Clonal Hematopoiesis, and Coronary Artery Disease in Postmenopausal Women. Circulation 143, 410–423, doi:10.1161/CIRCULATIONAHA.120.051775 (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1161/CIRCULATIONAHA.120.051775&link_type=DOI) 

24. Busque, L. et al. High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential. Blood Advances 4, 2430–2438, doi:10.1182/bloodadvances.2019000770 (2020).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1182/bloodadvances.2019000770&link_type=DOI) 

25. Coombs, C. C. et al. Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. Cell stem cell 21, 374-382.e374, doi:10.1016/j.stem.2017.07.010 (2017).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.stem.2017.07.010&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=28803919&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2022.08.20.22279019.atom) 

26. Zekavat, S. M. et al. TP53-mediated clonal hematopoiesis confers increased risk for incident peripheral artery disease. medRxiv, 2021.2008.2022.21262430, doi:10.1101/2021.08.22.21262430 (2022).
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NzoibWVkcnhpdiI7czo1OiJyZXNpZCI7czoyMToiMjAyMS4wOC4yMi4yMTI2MjQzMHYyIjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjIvMDgvMjIvMjAyMi4wOC4yMC4yMjI3OTAxOS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

27. Lin, S. H. et al. Incident disease associations with mosaic chromosomal alterations on autosomes, X and Y chromosomes: insights from a phenome-wide association study in the UK Biobank. Cell Biosci 11, 143, doi:10.1186/s13578-021-00651-z (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1186/s13578-021-00651-z&link_type=DOI) 

28. Forsberg, L. A. et al. Mosaic loss of chromosome Y in leukocytes matters. Nat Genet 51, 4–7, doi:10.1038/s41588-018-0267-9 (2019).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41588-018-0267-9&link_type=DOI) 

29. Loftfield, E. et al. Predictors of mosaic chromosome Y loss and associations with mortality in the UK Biobank. Scientific Reports 8, 12316, doi:10.1038/s41598-018-30759-1 (2018).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41598-018-30759-1&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=30120341&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2022.08.20.22279019.atom) 

30. Forsberg, L. A. et al. Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancer. Nature Genetics 46, 624–628, doi:10.1038/ng.2966 (2014).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/ng.2966&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=24777449&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2022.08.20.22279019.atom) 

31. Dumanski, J. P. et al. Mosaic Loss of Chromosome Y in Blood Is Associated with Alzheimer Disease. American journal of human genetics 98, 1208–1219, doi:10.1016/j.ajhg.2016.05.014 (2016).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.ajhg.2016.05.014&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=27231129&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2022.08.20.22279019.atom) 

32. Persani, L. et al. Increased loss of the Y chromosome in peripheral blood cells in male patients with autoimmune thyroiditis. Journal of autoimmunity 38, J193–196, doi:10.1016/j.jaut.2011.11.011 (2012).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jaut.2011.11.011&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=22196921&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2022.08.20.22279019.atom) 

33. Haitjema, S. et al. Loss of Y Chromosome in Blood Is Associated With Major Cardiovascular Events During Follow-Up in Men After Carotid Endarterectomy. Circulation. Cardiovascular genetics 10, e001544, doi:10.1161/circgenetics.116.001544 (2017).
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NzoiY2lyY2N2ZyI7czo1OiJyZXNpZCI7czoxMjoiMTAvNC9lMDAxNTQ0IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjIvMDgvMjIvMjAyMi4wOC4yMC4yMjI3OTAxOS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

34. Sturgeon, K. M. et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. European Heart Journal 40, 3889–3897, doi:10.1093/eurheartj/ehz766 (2019).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/eurheartj/ehz766&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2022.08.20.22279019.atom) 

35. Wang, S. et al. Prevalence and prognostic significance of DNMT3A- and TET2-clonal haematopoiesis-driver mutations in patients presenting with ST-segment elevation myocardial infarction. EBioMedicine 78, 103964, doi:10.1016/j.ebiom.2022.103964 (2022).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.ebiom.2022.103964&link_type=DOI) 

36. Bolton, K. L. et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nature Genetics 52, 1219–1226, doi:10.1038/s41588-020-00710-0 (2020).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41588-020-00710-0&link_type=DOI) 

37. Levin, M. G. et al. Genetics of smoking and risk of clonal hematopoiesis. Scientific Reports 12, 7248, doi:10.1038/s41598-022-09604-z (2022).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41598-022-09604-z&link_type=DOI) 

38. Machiela, M. J. et al. Female chromosome X mosaicism is age-related and preferentially affects the inactivated X chromosome. Nature Communications 7, 11843, doi:10.1038/ncomms11843 (2016).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/ncomms11843&link_type=DOI) 

39. Sano, S. et al. Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality. Science 377, 292–297, doi:doi:10.1126/science.abn3100 (2022).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1126/science.abn3100&link_type=DOI) 

40. Sudlow, C. et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS medicine 12, e1001779, doi:10.1371/journal.pmed.1001779 (2015).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pmed.1001779&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25826379&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2022.08.20.22279019.atom) 

41. Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 562, 203–209, doi:10.1038/s41586-018-0579-z (2018).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41586-018-0579-z&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=30305743&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2022.08.20.22279019.atom) 

42. Loh, P.-R. et al. Reference-based phasing using the Haplotype Reference Consortium panel. Nature Genetics 48, 1443–1448, doi:10.1038/ng.3679 (2016).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/ng.3679&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=27694958&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F22%2F2022.08.20.22279019.atom) 

43. Zekavat, S. M. et al. Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection. Nature Medicine 27, 1012–1024, doi:10.1038/s41591-021-01371-0 (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41591-021-01371-0&link_type=DOI) 

44. Wan, E. Y. F. et al. Blood Pressure and Risk of Cardiovascular Disease in UK Biobank. Hypertension 77, 367–375, doi:10.1161/HYPERTENSIONAHA.120.16138 (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1161/HYPERTENSIONAHA.120.16138&link_type=DOI) 

45. Sjoberg DD, Whiting K, Curry M, Lavery JA & j, L. Reproducible summary tables with the gtsummary package. The R Journal 13, 570–580 (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.32614/RJ-2021-053&link_type=DOI)